Virology and Immunology of HIV/AIDS

Virology and Immunology of HIV/AIDS: Core Concepts

Understanding HIV (Human Immunodeficiency Virus) and its progression to AIDS (Acquired Immunodeficiency Syndrome) requires a solid grasp of viral structure, the replication cycle, and the host immune response. This course synthesizes key points from a quiz format into a comprehensive, SEO‑friendly guide for medical students and healthcare professionals.

1. Viral Entry: The Role of gp120

The first step in HIV infection is the attachment of the virus to the target cell. The gp120 envelope glycoprotein mediates this critical interaction.

• gp120 binds to the CD4 receptor on helper T cells, macrophages, and dendritic cells.
• After CD4 engagement, a conformational change exposes the binding site for a chemokine co‑receptor (CCR5 or CXCR4).
• This dual‑receptor requirement determines viral tropism and influences disease progression.

Targeting gp120 with neutralizing antibodies is a major strategy in vaccine development.

2. Reverse Transcription: From RNA to DNA

Once inside the cell, HIV must convert its single‑stranded RNA genome into double‑stranded DNA. This conversion is catalyzed by the viral enzyme reverse transcriptase (RT).

• RT synthesizes a complementary DNA (cDNA) strand, then degrades the RNA template using its RNase H activity.
• A second DNA strand is synthesized, yielding a proviral DNA ready for integration.
• RT’s error‑prone nature contributes to the high mutation rate of HIV, complicating treatment.

3. Co‑Receptor Requirement: CD4 Plus CCR5 or CXCR4

Efficient infection demands co‑expression of CD4 and a chemokine co‑receptor:

• CCR5 is predominant in early infection and is expressed on macrophages and memory T cells.
• CXCR4 usage often emerges later, correlating with rapid CD4+ T‑cell decline.

Individuals with a homozygous CCR5‑Δ32 mutation are highly resistant to HIV infection, highlighting the therapeutic potential of co‑receptor blockers.

4. Integration: The Function of Integrase

After reverse transcription, the viral DNA is transported into the nucleus where the enzyme integrase inserts it into the host genome.

• Integration creates a stable provirus that can be transcribed whenever the host cell is activated.
• Integrase inhibitors (e.g., raltegravir, dolutegravir) block this step and are cornerstone drugs in modern antiretroviral therapy (ART).

5. Primary Cellular Targets

HIV primarily infects cells expressing CD4 and the appropriate co‑receptor. The main targets are:

• CD4+ T lymphocytes – central to adaptive immunity.
• Macrophages – serve as reservoirs in tissues.
• Dendritic cells – capture virus in mucosal sites and facilitate transmission to T cells.

In contrast, B lymphocytes lack CD4 and are not primary targets, although they can be indirectly affected by dysregulated immune activation.

6. Latency: Why HIV Persists for Years

The hallmark of HIV infection is its ability to remain silent for long periods. The key mechanism is:

• The proviral DNA integrates into host chromatin and can enter a transcriptionally silent state, forming a latent reservoir.
• Latently infected resting CD4+ T cells are long‑lived and evade immune detection and antiretroviral drugs, which target active replication.
• Reactivation can occur upon cellular activation, leading to viral rebound if therapy is stopped.

Eradicating these reservoirs is the focus of “cure” research, including latency‑reversing agents and immune‑based strategies.

7. Early Immune Control: CD8+ Cytotoxic T Lymphocytes

During primary infection, the innate and adaptive arms collaborate, but the most potent early suppressor of HIV replication is the CD8+ cytotoxic T lymphocyte (CTL) response.

• CTLs recognize viral peptides presented by MHC‑I on infected cells and induce apoptosis.
• Effective CTL responses correlate with lower viral set points and slower disease progression.
• HIV can escape CTL pressure through rapid mutation, underscoring the need for broad, multi‑epitope vaccines.

8. The Double‑Edged Sword of HIV‑Specific CD4+ T Helper Cells

CD4+ T helper cells are essential for orchestrating immune responses, yet they are also the virus’s primary target. This paradox creates a “double‑edged sword” in AIDS pathogenesis:

• These cells provide help to CD8+ T cells and B cells, enabling effective cytotoxic and antibody responses.
• Because they express the receptors required for viral entry, they become infected and depleted, undermining the very immunity they support.
• The loss of CD4+ T cells leads to immune dysregulation, opportunistic infections, and malignancies characteristic of AIDS.

9. Summary of Key Points

• gp120 mediates initial attachment to CD4 and a chemokine co‑receptor.
• Reverse transcriptase synthesizes DNA from the viral RNA genome.
• Effective infection requires CD4 + CCR5 or CXCR4 co‑expression.
• Integrase integrates proviral DNA into host chromosomes.
• Primary targets: CD4+ T cells, macrophages, dendritic cells; not B cells.
• Latency arises from integrated provirus that remains transcriptionally silent.
• Early viral control is driven by CD8+ cytotoxic T lymphocytes.
• HIV‑specific CD4+ T cells are both essential for immunity and vulnerable to infection.

10. Frequently Asked Questions (FAQ)

What makes gp120 a vaccine target?

gp120 is exposed on the viral surface and is essential for receptor binding. Neutralizing antibodies that block gp120 can prevent entry, making it a prime antigen for vaccine design.

Why are integrase inhibitors effective even after the virus has entered the cell?

Integrase acts after reverse transcription, before proviral DNA becomes permanently integrated. Inhibiting this step prevents the formation of a stable reservoir.

Can antiretroviral therapy eliminate latent reservoirs?

Current ART suppresses active replication but does not eradicate latently infected cells. Ongoing research aims to “shock and kill” or “block and lock” these reservoirs.